{
  "model_id": "TEDS-2026-v1",
  "concept": "Targeted Exosome Delivery System for Dermal Regeneration",
  "domain": "Dermatology / Regenerative Medicine",
  "target_cell": "Dermal Fibroblast (CD90+)",
  "mechanism": {
    "surface_engineering": "Anti-CD90 scFv conjugation",
    "delivery_vector": "Engineered Exosome (50-150nm)",
    "cargo": [
      "miR-21 (Collagen Type I/III promoter)",
      "TGF-beta1 mRNA",
      "Hyaluronic Acid Synthase 2 (HAS2) mRNA"
    ]
  },
  "predicted_outcomes": {
    "collagen_synthesis": "+40% vs non-targeted exosomes",
    "mmp_reduction": "-25% (MMP-1, MMP-3)",
    "fibroblast_proliferation": "Significant increase (p < 0.01)"
  },
  "safety_profile": {
    "immunogenicity": "Low (Human MSC-derived, immune-privileged)",
    "toxicity": "Negligible at therapeutic doses"
  },
  "clinical_relevance": {
    "indications": [
      "Photoaging",
      "Atrophic Scarring",
      "Post-procedure Healing"
    ],
    "limitations": "Requires precise dosing; manufacturing scalability challenges."
  },
  "status": "Internal Synthesis / Hypothesis Generation",
  "validation_required": true,
  "timestamp": "2026-02-14T17:50:00+09:00"
}
